A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma

BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) exert a cytotoxic and immune-mediated effect on metastatic melanoma. The immune-mediated mechanism can lead to some adverse events, including panniculitis, erythema, keratitis, vitiligo-like lesions, or, more rarely, sarcoid-like skin reactions. In p...

Full description

Bibliographic Details
Main Authors: Maria Chiara Tronconi, Arianna Marinello, Alessandra Solferino, Susanna Grimaudo, Michele Ciccarelli, Sofia Manara, Luca Cozzaglio, Luca Mancini, Riccardo Borroni, Armando Santoro
Format: Article
Language:English
Published: Karger Publishers 2022-05-01
Series:Case Reports in Oncology
Subjects:
melanoma
targeted therapy
dabrafenib
trametinib
sarcoidosis
immune-mediated event
Online Access:https://www.karger.com/Article/FullText/524185

Internet

https://www.karger.com/Article/FullText/524185

Similar Items